.png)
.png)
Latest news from BIA
BIA responds to the new letter from Government on the medicine supply contingency plan programme
Today the Health Secretary Matt Hancock has written to pharmaceutical companies to update them on progress made on human medicines supply in March 2019 “no deal scenario” with some updates to the Government planning assumptions.
BIA responds to second Life Sciences Sector Deal
Today the government has published the second Life Sciences Sector Deal. The document details both public and private sector investments into the sector, including a £1bn research and development investment from BIA member company UCB and a new partnership between government and industry using artificial intelligence to develop the next generation of treatments.
Action Medical Research for children named BIA Charity of the Year 2019
The BioIndustry Association has today announced that Action Medical Research for children will be its Charity of the Year for 2019. The partnership will be formally launched at the BIA Gala Dinner on 24 January 2019. Proceeds from a silent auction, table donations and pledges on the night will be donated to Action Medical Research for children, and attendees will hear from Simon Harriss, dad to 10-year-old Lily who has a devastating neurological condition called BPAN.
All Party Parliamentary Group to raise the profile of the UK Life Sciences sector
This week marked the relaunch of the All Party Parliamentary Group (APPG) for Life Sciences. Chaired by Daniel Zeichner MP, the APPG will raise awareness of UK life sciences among parliamentarians and explore the challenges and opportunities facing the sector.
First production and administration of Axumin® (fluciclovine (18F)) in France.
Blue Earth Diagnostics, a leading molecular imaging diagnostics company, yesterday announced that the first commercial production of Axumin® (fluciclovine (18F)) in France occurred recently, with the first French patients being dosed.
Discovery Park joins the life science and health care conversation at Genesis 2018
Discovery Park - and some of the businesses driving its success - will use one of the UK’s leading science events to showcase why it remains the perfect location for science companies looking to grow and collaborate. It will be attending Genesis 2018 with several of its life sciences tenants, showcasing their activities and discussing its plans for the future development of the Park.
Arecor to attend the 37th annual J.P. Morgan Healthcare Conference
Arecor Ltd, the UK-based specialty pharmaceutical company that develops superior biopharmaceuticals through the application of an innovative formulation technology platform, is pleased to announce today that its executive management team, Dr Sarah Howell (Chief Executive Officer) and Dr Jan Jezek (Chief Scientific Officer) will be attending the 37th Annual J.P. Morgan Healthcare Conference, San Francisco, CA.
Genomics plc today announces second close of its Series B financing, raising a further £8 million, bringing the total round to £33 million
10 December 2018, OXFORD, UK -- Genomics plc, the data science company specialising in the use of human genetic information to improve drug development, today announced that it has successfully completed a second close of its Series B financing round. The second close, which was oversubscribed, raised an additional £8 million, bringing the total raised in the round to £33 million.
CEO Update | Monday 10 December 2018
Expect ongoing Westminster drama on Brexit this week. We’ll monitor and respond appropriately on behalf of our members and then provide a Christmas wrapped analysis of what it all means for our sector on Wednesday 17th December at our final webinar of the year.
Impact of ELIXIR infrastructure
ELIXIR is an intergovernmental organisation that unites leading life science organisations in managing and safeguarding the increasing volume of data being generated. ELIXIR coordinates, integrates and sustains bioinformatics resources and services across its Nodes, and enables users in academia and industry to freely access services that are vital for their work.
Connecting the holy trinity: life science sector, academia and NHS data
Last week, Health Data Research UK (HDR UK) organised an industry workshop, with support from the BIA, to discuss the implementation of the Digital Innovation Hubs. The Hubs were first recommended in the Life Sciences Industrial Strategy and last week’s event marked a (small) step forward in making them a reality.
CEO Update | Monday 3 December
Today the government announced funding for a new Vaccines Manufacturing Innovation Centre to be built in Oxford. Led by the Jenner Institute, a partnership between the University of Oxford and the Pirbright Institute, the new centre has been awarded funding by UK Research and Innovation of £66 million through the UK government’s Industrial Strategy Challenge Fund (ISCF) Medicines Manufacturing challenge. Additional funding of £10 million will come from commercial and other partners, including Janssen Vaccines & Prevention B.V. and Merck Sharp and Dohme. The centre will be further supported by expertise and training from GE Healthcare. The core research teams will be drawn from academia and industry and will include significant new contributions from the London School of Hygiene & Tropical
Please find a selection of featured BIA publications below. To see our full publications library, click here.
Influencing and shaping our sector, BIA update: January - April 2018
This quarterly update gives an overview of key policy developments and the BIA’s continued engagement with policymakers, regulatory authorities and wider stakeholders on behalf of the UK life sciences industry, from January to April 2018.
Biotech Financing Update: December 2017 to February 2018
The BIA/Informa Biotech Financing Update: December 2017-February 2018 released today shows that venture capital financing and follow on financing on the public markets are off to a solid start in 2018.
Pipeline Progressing: The UK's Global Bioscience Cluster in 2017
A new report released by the BioIndustry Association (BIA) and Informa Pharma Intelligence reveals that the UK has the strongest clinical and preclinical pipeline in Europe.
BIA Best practice guide for communicating R&D
Ensuring investors and the wider public are well informed and confident about bioscience is crucial to the success of individual companies and the sector as a whole. To support the sector to maintain high standards in communications about R&D progress, the BIA has produced a best practice guide for bioscience companies with a supporting library of resources.
